# Tahseen Mozaffar

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/11424236/publications.pdf

Version: 2024-02-01

| | | | |
|---|---|---|---|
| 62 papers | 4,380 citations | 147801 31 h-index | 118850 62 g-index |
| 65 all docs | 65 docs citations | 65 times ranked | 4675 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Patient reported quality of life in limb girdle muscular dystrophy. Neuromuscular Disorders, 2022, 32, 57-64. | 0.6 | 3 |
| 2 | Loss of TDP-43 function and rimmed vacuoles persist after T cell depletion in a xenograft model of sporadic inclusion body myositis. Science Translational Medicine, 2022, 14, eabi9196. | 12.4 | 27 |
| 3 | Development of a standard of care for patients with valosin-containing protein associated multisystem proteinopathy. Orphanet Journal of Rare Diseases, 2022, 17, 23. | 2.7 | 19 |
| 4 | Multisystem proteinopathy: Where myopathy and motor neuron disease converge. Muscle and Nerve, 2021, 63, 442-454. | 2.2 | 33 |
| 5 | Clinical utility of antiâ€cytosolic 5â€™â€nucleotidase 1A antibody in idiopathic inflammatory myopathies. Annals of Clinical and Translational Neurology, 2021, 8, 571-578. | 3.7 | 18 |
| 6 | Results from a 3-year Non-interventional, Observational Disease Monitoring Program in Adults with GNE Myopathy. Journal of Neuromuscular Diseases, 2021, 8, 225-234. | 2.6 | 9 |
| 7 | A stromal progenitor and ILC2 niche promotes muscle eosinophilia and fibrosis-associated gene expression. Cell Reports, 2021, 35, 108997. | 6.4 | 28 |
| 8 | Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurology, The, 2021, 20, 526-536. | 10.2 | 194 |
| 9 | IgG regulation through FcRn blocking: A novel mechanism for the treatment of myasthenia gravis. Journal of the Neurological Sciences, 2021, 430, 118074. | 0.6 | 24 |
| 10 | Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial. Lancet Neurology, The, 2021, 20, 1027-1037. | 10.2 | 42 |
| 11 | Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial. Lancet Neurology, The, 2021, 20, 1012-1026. | 10.2 | 59 |
| 12 | Examination of the human motor endplate after brachial plexus injury with twoâ€photon microscopy. Muscle and Nerve, 2020, 61, 390-395. | 2.2 | 6 |
| 13 | Update on immuneâ€mediated therapies for myasthenia gravis. Muscle and Nerve, 2020, 62, 579-592. | 2.2 | 9 |
| 14 | Minimal manifestation status and prednisone withdrawal in the MGTX trial. Neurology, 2020, 95, e755-e766. | 1.1 | 17 |
| 15 | Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis. JAMA Neurology, 2020, 77, 582. | 9.0 | 126 |
| 16 | Plasma creatinine and oxidative stress biomarkers in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 263-272. | 1.7 | 20 |
| 17 | Limbâ€girdle muscular dystrophy: A perspective from adult patients on what matters most. Muscle and Nerve, 2019, 60, 419-424. | 2.2 | 15 |
| 18 | A phase 3 randomized study evaluating sialic acid extended-release for GNE myopathy. Neurology, 2019, 92, e2109-e2117. | 1.1 | 40 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial. Lancet Neurology, The, 2019, 18, 259-268. | 10.2 | 139 |
| 20 | Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis. Neurology, 2019, 92, e2661-e2673. | 1.1 | 169 |
| 21 | First-in-human study of advanced and targeted acid Î±-glucosidase (AT-GAA) (ATB200/AT2221) in patients with Pompe disease: preliminary functional assessment results from the ATB200-02 trial. Molecular Genetics and Metabolism, 2019, 126, S86. | 1.1 | 4 |
| 22 | 237th ENMC International Workshop: GNE myopathy â€“ current and future research Hoofddorp, The Netherlands, 14â€“16 September 2018. Neuromuscular Disorders, 2019, 29, 401-410. | 0.6 | 5 |
| 23 | New family with HSPB 8-associated autosomal dominant rimmed vacuolar myopathy. Neurology: Genetics, 2019, 5, e349. | 1.9 | 24 |
| 24 | QuantiMus: A Machine Learning-Based Approach for High Precision Analysis of Skeletal Muscle Morphology. Frontiers in Physiology, 2019, 10, 1416. | 2.8 | 35 |
| 25 | Rasagiline for amyotrophic lateral sclerosis: A randomized, controlled trial. Muscle and Nerve, 2019, 59, 201-207. | 2.2 | 35 |
| 26 | Longitudinal Screening Detects Cognitive Stability and Behavioral Deterioration in ALS Patients. Behavioural Neurology, 2018, 2018, 1-7. | 2.1 | 19 |
| 27 | Review process for IVIg treatment. Neurology: Clinical Practice, 2018, 8, 429-436. | 1.6 | 9 |
| 28 | Novel Therapeutic Options in Treatment of Idiopathic Inflammatory Myopathies. Current Treatment Options in Neurology, 2018, 20, 37. | 1.8 | 2 |
| 29 | A cross-sectional analysis of clinical evaluation in 35 individuals with mutations of the valosin-containing protein gene. Neuromuscular Disorders, 2018, 28, 778-786. | 0.6 | 7 |
| 30 | Mortality and Causes of Death in Patients with Sporadic Inclusion Body Myositis: Survey Study Based on the Clinical Experience of Specialists in Australia, Europe and the USA. Journal of Neuromuscular Diseases, 2016, 3, 67-75. | 2.6 | 44 |
| 31 | Sporadic inclusion body myositis misdiagnosed as idiopathic granulomatous myositis. Neuromuscular Disorders, 2016, 26, 741-743. | 0.6 | 7 |
| 32 | Randomized Trial of Thymectomy in Myasthenia Gravis. New England Journal of Medicine, 2016, 375, 511-522. | 27.0 | 695 |
| 33 | 215th ENMC International Workshop VCP-related multi-system proteinopathy (IBMPFD) 13â€“15 November 2015, Heemskerk, The Netherlands. Neuromuscular Disorders, 2016, 26, 535-547. | 0.6 | 38 |
| 34 | Prospective exploratory muscle biopsy, imaging, and functional assessment in patients with late-onset Pompe disease treated with alglucosidase alfa: The EMBASSY Study. Molecular Genetics and Metabolism, 2016, 119, 115-123. | 1.1 | 49 |
| 35 | A randomized controlled trial of methotrexate for patients with generalized myasthenia gravis. Neurology, 2016, 87, 57-64. | 1.1 | 106 |
| 36 | Cognitive-behavioral screening reveals prevalent impairment in a large multicenter ALS cohort. Neurology, 2016, 86, 813-820. | 1.1 | 70 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Pulmonary function tests (maximum inspiratory pressure, maximum expiratory pressure, vital capacity,) Tj ETQq1 1 0.784314 rgBT /O 2016, 26, 136-145. | 0.6 | 31 |
| 38 | An overview of polymyositis and dermatomyositis. Muscle and Nerve, 2015, 51, 638-656. | 2.2 | 176 |
| 39 | Topical Tranexamic Acid Does Not Affect Electrophysiologic or Neurovascular Sciatic Nerve Markers in an Animal Model. Clinical Orthopaedics and Related Research, 2015, 473, 1074-1082. | 1.5 | 8 |
| 40 | Desert hedgehog is a mediator of demyelination in compression neuropathies. Experimental Neurology, 2015, 271, 84-94. | 4.1 | 17 |
| 41 | ALS Multicenter Cohort Study of Oxidative Stress (ALS COSMOS): Study methodology, recruitment, and baseline demographic and disease characteristics. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2014, 15, 192-203. | 1.7 | 35 |
| 42 | Lipid-enriched diet rescues lethality and slows down progression in a murine model of VCP-associated disease. Human Molecular Genetics, 2014, 23, 1333-1344. | 2.9 | 20 |
| 43 | Targeting the Wnt/ÃŸ-Catenin Signaling Pathway After Traumatic Nerve Injury to Improve Functional Recovery. Journal of Hand Surgery, 2014, 39, e13-e14. | 1.6 | 0 |
| 44 | Experimental trials in amyotrophic lateral sclerosis: a review of recently completed, ongoing and planned trials using existing and novel drugs. Expert Opinion on Investigational Drugs, 2014, 23, 1541-1551. | 4.1 | 35 |
| 45 | Early Surgical Decompression Restores Neurovascular Blood Flow and Ischemic Parameters in an in Vivo Animal Model of Nerve Compression Injury. Journal of Bone and Joint Surgery - Series A, 2014, 96, 897-906. | 3.0 | 29 |
| 46 | A randomized, doubleâ€blind, placeboâ€controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis. Muscle and Nerve, 2013, 48, 76-84. | 2.2 | 187 |
| 47 | A progressive translational mouse model of human valosinâ€containing protein disease: The VCP<sup>R155H/+</sup> mouse. Muscle and Nerve, 2013, 47, 260-270. | 2.2 | 58 |
| 48 | Matrix metalloproteinase 3 deletion preserves denervated motor endplates after traumatic nerve injury. Annals of Neurology, 2013, 73, 210-223. | 5.3 | 47 |
| 49 | Valosin-containing protein mutation and Parkinsonâ€™s disease. Parkinsonism and Related Disorders, 2012, 18, 107-109. | 2.2 | 53 |
| 50 | Biophysical stimulation induces demyelination via an integrinâ€dependent mechanism. Annals of Neurology, 2012, 72, 112-123. | 5.3 | 14 |
| 51 | Chronic nerve compression alters schwann cell myelin architecture in a murine model. Muscle and Nerve, 2012, 45, 231-241. | 2.2 | 50 |
| 52 | The Homozygote VCPR155H/R155H Mouse Model Exhibits Accelerated Human VCP-Associated Disease Pathology. PLoS ONE, 2012, 7, e46308. | 2.5 | 56 |
| 53 | Compressive Neuropathies of the Upper Extremity: Update on Pathophysiology, Classification, and Electrodiagnostic Findings. Journal of Hand Surgery, 2010, 35, 668-677. | 1.6 | 76 |
| 54 | Neuromuscular junction integrity after chronic nerve compression injury. Journal of Orthopaedic Research, 2009, 27, 114-119. | 2.3 | 14 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | A novel, efficient, randomized selection trial comparing combinations of drug therapy for ALS. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2008, 9, 212-222. | 2.1 | 67 |
| 56 | The Role of Neurodiagnostic Studies in Nerve Injuries and Other Orthopedic Disorders. Journal of Hand Surgery, 2007, 32, 1280-1290. | 1.6 | 13 |
| 57 | Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurology, The, 2007, 6, 1045-1053. | 10.2 | 610 |
| 58 | Local down-regulation of myelin-associated glycoprotein permits axonal sprouting with chronic nerve compression injury. Experimental Neurology, 2006, 200, 418-429. | 4.1 | 54 |
| 59 | Schwann cells upregulate vascular endothelial growth factor secondary to chronic nerve compression injury. Muscle and Nerve, 2005, 31, 452-460. | 2.2 | 52 |
| 60 | Chronic nerve compression induces local demyelination and remyelination in a rat model of carpal tunnel syndrome. Experimental Neurology, 2004, 187, 500-508. | 4.1 | 110 |
| 61 | Macrophage Recruitment Follows the Pattern of Inducible Nitric Oxide Synthase Expression in a Model for Carpal Tunnel Syndrome. Journal of Neurotrauma, 2003, 20, 671-680. | 3.4 | 26 |
| 62 | Clinical correlates of granulomas in muscle. Journal of Neurology, 1998, 245, 519-524. | 3.6 | 56 |